Collegium Q2: Azstarys Integration Lifts Revenue, but Acquisition Costs Drag Bottom Line into the Red
COLL is trading near its 52-week low of $29.7 (7.2% above the low).
Summary
Collegium posted Q2 revenue of $199.9M, up 6% year-over-year, but swung to a $15.1M net loss as $23.3M in Azstarys acquisition costs and higher amortization overwhelmed top-line gains from Jornay PM and the new ADHD drug.
Key Events · Earnings and Guidance · COLL
-
Q2 Net Loss of $15.1M
A net loss of $15.1M ($0.46/share) replaced the prior year's net income of $12.0M, weighed down by $23.3M in Azstarys acquisition-related expenses and a $7.5M increase in intangible amortization.
-
Revenue Up 6% to $199.9M
Jornay PM revenue surged 41% to $46.1M, Azstarys contributed $12.9M in its first partial quarter, and Belbuca grew 10% to $57.7M, offsetting declines in Xtampza ER (-14%) and Nucynta branded products.
-
Cash Burned by Azstarys Deal
Cash and equivalents fell to $129.5M from $231.3M at year-end, with $655.4M paid for Azstarys (net of cash acquired), partially funded by a $300M delayed-draw term loan and $151.8M in securities sales.
-
Debt Load Rises to $1.09B
Total debt increased to $1.09B (term loan $852.8M, convertible notes $238.7M) after drawing the delayed-draw term loan for Azstarys. Q2 interest expense was $19.5M.
Analysis · COLL · Life Sciences
The first full quarter with Azstarys underscores the strategic rationale: revenue climbed 6% to $199.9M, powered by a 41% surge in Jornay PM and a $12.9M contribution from Azstarys in just seven weeks. Yet the deal's price tag is stark—$23.3M in acquisition-related expenses and higher amortization from the $635M intangible asset pushed the company to a $15.1M net loss. Cash burned by $101.8M in the half, and total debt now stands at $1.09B. Meanwhile, the core pain franchise is eroding: Xtampza ER fell 14%, and Nucynta branded products dropped sharply as authorized generics launched. The ADHD pivot is delivering on the top line, but the balance sheet is stretched and profitability remains under pressure until integration costs fade.
At the time of this filing, COLL was trading at $31.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $29.70 to $50.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.